Regeneron's 'Strong Commercial' Q3 Underscores Core Business Health, RBC Capital Markets Says

MT Newswires Live00:40

Regeneron Pharmaceuticals' (REGN) "strong commercial" Q3 underscores the health of its core businesses, supported by continued growth in the Dupixent and Eylea franchises, RBC Capital Markets said in a note emailed Monday.

The company's "successful" defense against ophthalmology biosimilars and the multiple tools available to protect Dupixent should support revenue durability, while the Sanofi (SNY) payoff could provide greater benefits to the bottom line, according to the note.

The investment firm said, however, that the company's pipeline needs to produce clearer standout winners to drive long-term growth and further outperformance versus peers.

The firm said it sees underappreciated medium-term growth from Dupixent, pipeline and the Sanofi repayment, but said substantial near-term outperformance would likely require success of a multibillion-dollar pipeline drug, a Dupixent growth inflection, or greater clarity around the drug's life cycle.

RBC Capital Markets has a sector perform rating on Regeneron Pharmaceuticals and raised its price target to $913 from $810.

Regeneron Pharmaceuticals shares were up 4% in Monday trading.

Price: 965.08, Change: +37.19, Percent Change: +4.01

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2680761537?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-11-03 00:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2680761537","market":"fut","top_or_hot":-1,"title":"Regeneron's 'Strong Commercial' Q3 Underscores Core Business Health, RBC Capital Markets Says","media":"MT Newswires Live","content":"<html><body><p> Regeneron Pharmaceuticals' (REGN) \"strong commercial\" Q3 underscores the health of its core businesses, supported by continued growth in the Dupixent and Eylea franchises, RBC Capital Markets said in a note emailed Monday.</p><p>The company's \"successful\" defense against ophthalmology biosimilars and the multiple tools available to protect Dupixent should support revenue durability, while the <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (SNY) payoff could provide greater benefits to the bottom line, according to the note.</p><p>The investment firm said, however, that the company's pipeline needs to produce clearer standout winners to drive long-term growth and further outperformance versus peers.</p><p>The firm said it sees underappreciated medium-term growth from Dupixent, pipeline and the <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> repayment, but said substantial near-term outperformance would likely require success of a multibillion-dollar pipeline drug, a Dupixent growth inflection, or greater clarity around the drug's life cycle.</p><p>RBC Capital Markets has a sector perform rating on Regeneron Pharmaceuticals and raised its price target to $913 from $810.</p><p>Regeneron Pharmaceuticals shares were up 4% in Monday trading.</p><p>Price: 965.08, Change: +37.19, Percent Change: +4.01</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's 'Strong Commercial' Q3 Underscores Core Business Health, RBC Capital Markets Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's 'Strong Commercial' Q3 Underscores Core Business Health, RBC Capital Markets Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-11-03 00:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Regeneron Pharmaceuticals' (REGN) \"strong commercial\" Q3 underscores the health of its core businesses, supported by continued growth in the Dupixent and Eylea franchises, RBC Capital Markets said in a note emailed Monday.</p><p>The company's \"successful\" defense against ophthalmology biosimilars and the multiple tools available to protect Dupixent should support revenue durability, while the <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (SNY) payoff could provide greater benefits to the bottom line, according to the note.</p><p>The investment firm said, however, that the company's pipeline needs to produce clearer standout winners to drive long-term growth and further outperformance versus peers.</p><p>The firm said it sees underappreciated medium-term growth from Dupixent, pipeline and the <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> repayment, but said substantial near-term outperformance would likely require success of a multibillion-dollar pipeline drug, a Dupixent growth inflection, or greater clarity around the drug's life cycle.</p><p>RBC Capital Markets has a sector perform rating on Regeneron Pharmaceuticals and raised its price target to $913 from $810.</p><p>Regeneron Pharmaceuticals shares were up 4% in Monday trading.</p><p>Price: 965.08, Change: +37.19, Percent Change: +4.01</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0708994859.HKD","symbol_name":"TEMPLETON GLOBAL \"A\" (HKD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2680761537","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2680761537","pubTimestamp":1793637604,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Regeneron Pharmaceuticals'  \"strong commercial\" Q3 underscores the health of its core businesses, supported by continued growth in the Dupixent and Eylea franchises, RBC Capital Markets said in a note emailed Monday.The company's \"successful\" defense against ophthalmology biosimilars and the multiple tools available to protect Dupixent should support revenue durability, while the Sanofi  payoff could provide greater benefits to the bottom line, according to the note.The investment firm said, however, that the company's pipeline needs to produce clearer standout winners to drive long-term growth and further outperformance versus peers.The firm said it sees underappreciated medium-term growth from Dupixent, pipeline and the Sanofi repayment, but said substantial near-term outperformance would likely require success of a multibillion-dollar pipeline drug, a Dupixent growth inflection, or greater clarity around the drug's life cycle.RBC Capital Markets has a sector perform rating on Regene","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","TBXU":"Direxion Daily Biotech Top 5 Bull 2X ETF","REGN":"再生元制药公司","GSIB":"THEMES GLOBAL SYSTEMICALLY IMPORTANT BANKS ETF","LU0882574055.USD":"富达全球健康医疗A ACC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4007":"制药","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","SNY":"赛诺菲安万特","LU0058720904.USD":"联博国际健康护理基金A","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IBB":"生物科技指数ETF-iShares Nasdaq","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","BBH":"VanEck Biotech ETF","BK4588":"碎股","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","IBBQ":"Invesco Nasdaq Biotechnology ETF","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1917777945.USD":"安联专题基金Cl AT Acc","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","BK4207":"综合性银行"},"translate_title":"加拿大皇家银行资本市场表示，再生元第三季度“强劲的商业”凸显核心业务健康状况","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":1,"IBBQ":0.6,"REGN":1,"TBXU":0.6,"GSIB":0.6,"BBH":0.6,"IBB":0.6},"content_text":"Regeneron Pharmaceuticals' (REGN) \"strong commercial\" Q3 underscores the health of its core businesses, supported by continued growth in the Dupixent and Eylea franchises, RBC Capital Markets said in a note emailed Monday.The company's \"successful\" defense against ophthalmology biosimilars and the multiple tools available to protect Dupixent should support revenue durability, while the Sanofi (SNY) payoff could provide greater benefits to the bottom line, according to the note.The investment firm said, however, that the company's pipeline needs to produce clearer standout winners to drive long-term growth and further outperformance versus peers.The firm said it sees underappreciated medium-term growth from Dupixent, pipeline and the Sanofi repayment, but said substantial near-term outperformance would likely require success of a multibillion-dollar pipeline drug, a Dupixent growth inflection, or greater clarity around the drug's life cycle.RBC Capital Markets has a sector perform rating on Regeneron Pharmaceuticals and raised its price target to $913 from $810.Regeneron Pharmaceuticals shares were up 4% in Monday trading.Price: 965.08, Change: +37.19, Percent Change: +4.01","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2680761537","isCrawlerRequest":true}